movement at the station, page-8

People are talking 3c after announcement.

I for one have been very frustrated with the management of the company. But that is only for one reason - I don't think we are harnessing PNO's potential.

If things all lined up, 3c is still undervaluing PNO.

It will have a product on the shelves generating revenue. From all accounts, it is a superior product to its competitors. This means we should expect high sales figures over time.

On top of this, we have at least two other products in the pipeline, which, arguably, will be a far greater success than thermalife.

Once tripeptofen is ready, watch out.

If the company was properly valued, it should be at 5c. But will probably settle at 3c once this announcement is out.